Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553772 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT02553772: Completed Phase 3 study, sponsored by Allergan.
NCT02553772 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 242 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02553772, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.
Primary Outcome
The OSDI© consists of 12 questions the patient is asked measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale where 0=none of the time and 4=all of the time. The score is converted to a 0 to 100-point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement.
Interventions
- DRUG Carboxymethylcellulose Based Eye Drop
- DRUG Carboxymethylcellulose Sodium 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2016-09-09 |
| Phase | Phase 3 |
What the finished NCT02553772 record still lists
NCT02553772 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Carboxymethylcellulose Based Eye Drop is the first listed.
NCT02553772 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02553772 about?
NCT02553772 is a clinical study titled "A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.". This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.
What is the current status of trial NCT02553772?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2016-01-06. Estimated completion is 2016-09-09.
What interventions are being tested in trial NCT02553772?
The interventions under investigation include: Carboxymethylcellulose Based Eye Drop (DRUG), Carboxymethylcellulose Sodium 0.5% (DRUG).
Who is sponsoring clinical trial NCT02553772?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02553772's enrollment target sits among peer trials
242 1270th of 2000 higher than 729 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI